Published in Mol Vis on May 30, 2003
RNA and disease. Cell (2009) 7.98
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov (2010) 4.25
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest (2007) 2.78
miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell (2008) 2.57
Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev (2009) 2.30
Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist. Proc Natl Acad Sci U S A (2004) 2.25
siRNA relieves chronic neuropathic pain. Nucleic Acids Res (2004) 1.96
Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res (2010) 1.79
Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci (2008) 1.76
Recent perspectives in ocular drug delivery. Pharm Res (2008) 1.72
Cell cycle regulator E2F1 modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A (2006) 1.66
Targeted disruption of outer limiting membrane junctional proteins (Crb1 and ZO-1) increases integration of transplanted photoreceptor precursors into the adult wild-type and degenerating retina. Cell Transplant (2010) 1.64
Silencing of Fas, but not caspase-8, in lung epithelial cells ameliorates pulmonary apoptosis, inflammation, and neutrophil influx after hemorrhagic shock and sepsis. Am J Pathol (2005) 1.60
Nonviral methods for siRNA delivery. Mol Pharm (2009) 1.50
Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol (2006) 1.39
Animal models of age related macular degeneration. Mol Aspects Med (2012) 1.39
Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest (2007) 1.34
Gene therapy in ophthalmology. Oman J Ophthalmol (2009) 1.24
Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol (2006) 1.21
Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery (2007) 1.17
Post-transcriptional regulation of vascular endothelial growth factor: implications for tumor angiogenesis. World J Gastroenterol (2006) 1.12
Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res (2007) 1.12
Role of rho kinase in the functional and dysfunctional tonic smooth muscles. Trends Pharmacol Sci (2011) 1.09
Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2008) 1.05
Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. Gene Regul Syst Bio (2008) 1.05
Regulation of the endogenous VEGF-A gene by exogenous designed regulatory proteins. Proc Natl Acad Sci U S A (2004) 1.04
Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. Am J Pathol (2007) 1.01
Long-term RNA interference gene therapy in a dominant retinitis pigmentosa mouse model. Proc Natl Acad Sci U S A (2011) 1.01
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm (2012) 1.00
Small interfering RNA-mediated suppression of Ccl2 in Müller cells attenuates microglial recruitment and photoreceptor death following retinal degeneration. J Neuroinflammation (2012) 0.98
Glioma angiogenesis: Towards novel RNA therapeutics. Cell Adh Migr (2009) 0.98
Rescue of pituitary function in a mouse model of isolated growth hormone deficiency type II by RNA interference. Endocrinology (2007) 0.97
Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo. PLoS One (2011) 0.96
Vector platforms for gene therapy of inherited retinopathies. Prog Retin Eye Res (2014) 0.94
Therapeutic regulation of gene expression in the inner ear using RNA interference. Adv Otorhinolaryngol (2009) 0.94
Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol Vis (2008) 0.90
Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP. J Exp Clin Cancer Res (2010) 0.90
Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1. Prostaglandins Other Lipid Mediat (2007) 0.89
Device-based local delivery of siRNA against mammalian target of rapamycin (mTOR) in a murine subcutaneous implant model to inhibit fibrous encapsulation. J Control Release (2010) 0.88
Gene silencing by RNAi in mouse Sertoli cells. Reprod Biol Endocrinol (2008) 0.88
PlGF gene knockdown in human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol (2010) 0.88
Age-related macular degeneration and the other double helix. The Cogan Lecture. Invest Ophthalmol Vis Sci (2011) 0.88
Down-regulation of inducible co-stimulator (ICOS) by intravitreal injection of small interfering RNA (siRNA) plasmid suppresses ongoing experimental autoimmune uveoretinitis in rats. Graefes Arch Clin Exp Ophthalmol (2009) 0.88
Non-viral siRNA delivery into the mouse retina in vivo. BMC Ophthalmol (2010) 0.88
A reproducible and quantifiable model of choroidal neovascularization induced by VEGF A165 after subretinal adenoviral gene transfer in the rabbit. Mol Vis (2008) 0.86
Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference. Invest Ophthalmol Vis Sci (2008) 0.86
Small interference RNA targeting TLR4 gene effectively attenuates pulmonary inflammation in a rat model. J Biomed Biotechnol (2012) 0.86
A universal protein tag for delivery of SiRNA-aptamer chimeras. Sci Rep (2013) 0.85
Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cells by targeting HIF-1alpha with short hairpin RNA-expressing plasmid DNA in human RPE cells in a coculture system. Graefes Arch Clin Exp Ophthalmol (2008) 0.85
Aflibercept for the treatment of age-related macular degeneration. Ophthalmol Ther (2013) 0.85
Pegylated siRNA-loaded calcium phosphate nanoparticle-driven amplification of cancer cell internalization in vivo. Biomaterials (2013) 0.85
Nonviral ocular gene therapy: assessment and future directions. Curr Opin Mol Ther (2008) 0.85
Silencing of P2Y(2) receptors reduces intraocular pressure in New Zealand rabbits. Br J Pharmacol (2012) 0.83
Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy. Br J Pharmacol (2013) 0.83
In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther (2013) 0.83
Sonoporation using microbubbles promotes lipofectamine-mediated siRNA transduction to rat retina. Bosn J Basic Med Sci (2011) 0.83
Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis. Recent Pat Biomed Eng (2012) 0.82
Cationic nano-copolymers mediated IKKbeta targeting siRNA inhibit the proliferation of human Tenon's capsule fibroblasts in vitro. Mol Vis (2008) 0.82
Protein kinase Cα downregulation via siRNA-PKCα released from foldable capsular vitreous body in cultured human retinal pigment epithelium cells. Int J Nanomedicine (2011) 0.82
Emerging techniques to treat corneal neovascularisation. Eye (Lond) (2011) 0.82
Lentivirus-mediated RNA interference of vascular endothelial growth factor in monkey eyes with iris neovascularization. Mol Vis (2010) 0.81
Renewing the assault on mRNA. Biotechnol Healthc (2004) 0.81
Bevasiranib for the treatment of wet, age-related macular degeneration. Ophthalmol Eye Dis (2010) 0.81
Multigenic lentiviral vectors for combined and tissue-specific expression of miRNA- and protein-based antiangiogenic factors. Mol Ther Methods Clin Dev (2015) 0.81
RNA therapeutics targeting osteoclast-mediated excessive bone resorption. Adv Drug Deliv Rev (2011) 0.80
Age-related macular degeneration: experimental and emerging treatments. Clin Ophthalmol (2009) 0.80
The inhibitory effect of small interference RNA protein kinase C-alpha on the experimental proliferative vitreoretinopathy induced by dispase in mice. Int J Nanomedicine (2013) 0.79
CTGFsiRNA ameliorates retinal cells apoptosis in streptozotocin-induced diabetic rats. Int J Ophthalmol (2010) 0.78
The effects of small interfering RNA-targeting tissue factor on an in vitro model of neovascularization. Mol Vis (2013) 0.78
Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer (2010) 0.77
Impact of Lycium Barbarum Polysaccharide and Danshensu on vascular endothelial growth factor in the process of retinal neovascularization of rabbit. Int J Ophthalmol (2013) 0.77
Immunostimulatory motifs enhance antiviral siRNAs targeting highly pathogenic avian influenza H5N1. PLoS One (2011) 0.77
Downregulation of transforming growth factor-β type II receptor prohibit epithelial-to-mesenchymal transition in lens epithelium. Mol Vis (2012) 0.77
Targeted suppression of heme oxygenase-1 by small interference RNAs inhibits the production of bilirubin in neonatal rat with hyperbilirubinemia. BMC Mol Biol (2009) 0.77
Pharmacokinetics and biodistribution of recently-developed siRNA nanomedicines. Adv Drug Deliv Rev (2015) 0.76
PEI-g-PEG-RGD/small interference RNA polyplex-mediated silencing of vascular endothelial growth factor receptor and its potential as an anti-angiogenic tumor therapeutic strategy. Oligonucleotides (2011) 0.76
Silencing genes in the kidney: antisense or RNA interference? Nephrol Dial Transplant (2008) 0.76
Vascular Endothelial Growth Factor Gene Polymorphism is not Associated with Diabetic Retinopathy in Egyptian Patients. Middle East Afr J Ophthalmol (2016) 0.75
Association of toll-like receptor 3 polymorphism rs3775291 with age-related macular degeneration: a systematic review and meta-analysis. Sci Rep (2016) 0.75
Exploring the role of VEGF in Indian Age related macular degeneration. Ann Neurosci (2015) 0.75
Silencing Myostatin Using Cholesterol-conjugated siRNAs Induces Muscle Growth. Mol Ther Nucleic Acids (2016) 0.75
Coupling Aptamers to Short Interfering RNAs as Therapeutics. Pharmaceuticals (Basel) (2011) 0.75
[siRNA in macular degeneration]. Ophthalmologe (2010) 0.75
Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 17.21
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet (2009) 6.71
Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther (2005) 4.74
Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success. Proc Natl Acad Sci U S A (2005) 4.04
Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther (2009) 3.93
HDAC6 controls autophagosome maturation essential for ubiquitin-selective quality-control autophagy. EMBO J (2010) 3.90
Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer. Mol Ther (2008) 3.28
AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med (2012) 2.87
Impairment of the transient pupillary light reflex in Rpe65(-/-) mice and humans with leber congenital amaurosis. Invest Ophthalmol Vis Sci (2004) 2.72
In utero gene therapy rescues vision in a murine model of congenital blindness. Mol Ther (2004) 2.56
Retracted Intravitreal injection of vascular endothelial growth factor small interfering RNA inhibits growth and leakage in a nonhuman primate, laser-induced model of choroidal neovascularization. Retina (2004) 2.43
Serotype-dependent packaging of large genes in adeno-associated viral vectors results in effective gene delivery in mice. J Clin Invest (2008) 2.40
Mutations in ABCA4 result in accumulation of lipofuscin before slowing of the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet (2004) 2.30
Lateral connectivity and contextual interactions in macaque primary visual cortex. Neuron (2002) 2.16
Safety of recombinant adeno-associated virus type 2-RPE65 vector delivered by ocular subretinal injection. Mol Ther (2006) 2.13
Lighting a candle in the dark: advances in genetics and gene therapy of recessive retinal dystrophies. J Clin Invest (2010) 2.13
TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. J Neurosci (2010) 2.05
Eye movement recordings as an effectiveness indicator of gene therapy in RPE65-deficient canines: implications for the ocular motor system. Invest Ophthalmol Vis Sci (2006) 2.01
A Propensity-Matched Analysis of the Influence of Breast Reconstruction on Subsequent Development of Lymphedema. Plast Reconstr Surg (2015) 1.97
Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital Amaurosis type 2. Ophthalmology (2013) 1.85
Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis. Hum Gene Ther (2006) 1.81
Novel AAV serotypes for improved ocular gene transfer. J Gene Med (2008) 1.80
Bilateral angle closure glaucoma in a child receiving oral topiramate. J AAPOS (2003) 1.68
Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus. Vision Res (2003) 1.63
AAV-mediated gene therapy for choroideremia: preclinical studies in personalized models. PLoS One (2013) 1.62
Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey. Sci Transl Med (2011) 1.54
Light damage induced changes in mouse retinal gene expression. Exp Eye Res (2004) 1.54
Traumatic retinal break from viscoelastic cannula during cataract surgery. Arch Ophthalmol (2003) 1.54
The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest (2011) 1.52
Single-field fundus photography for diabetic retinopathy screening: a report by the American Academy of Ophthalmology. Ophthalmology (2004) 1.50
Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci U S A (2002) 1.50
Mutations in RPGR and RP2 account for 15% of males with simplex retinal degenerative disease. Invest Ophthalmol Vis Sci (2012) 1.47
Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis. Mult Scler (2006) 1.44
ABCA4-associated retinal degenerations spare structure and function of the human parapapillary retina. Invest Ophthalmol Vis Sci (2005) 1.40
Systemic but not intraocular Epo gene transfer protects the retina from light-and genetic-induced degeneration. Mol Ther (2004) 1.35
Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness. Sci Transl Med (2010) 1.35
Disruption of intraflagellar protein transport in photoreceptor cilia causes Leber congenital amaurosis in humans and mice. J Clin Invest (2011) 1.31
Cdc42 and Rab8a are critical for intestinal stem cell division, survival, and differentiation in mice. J Clin Invest (2012) 1.31
Induction of inflammation by West Nile virus capsid through the caspase-9 apoptotic pathway. Emerg Infect Dis (2002) 1.30
Herpes simplex virus type 1 glycoprotein e is required for axonal localization of capsid, tegument, and membrane glycoproteins. J Virol (2005) 1.29
Tie2Cre-mediated inactivation of plexinD1 results in congenital heart, vascular and skeletal defects. Dev Biol (2008) 1.29
Breast reconstruction after breast cancer. Plast Reconstr Surg (2011) 1.28
Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis (2004) 1.27
Progress in gene therapy for neurological disorders. Nat Rev Neurol (2013) 1.22
Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16. Mol Cell Proteomics (2005) 1.21
Risk factors for choroidal neovascularization and vision loss in the fellow eye study of CNVPT. Retina (2003) 1.18
Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther (2011) 1.16
In vivo delivery of recombinant viruses to the fetal murine cochlea: transduction characteristics and long-term effects on auditory function. Mol Ther (2006) 1.15
Deficiency of SPAG16L causes male infertility associated with impaired sperm motility. Biol Reprod (2005) 1.14
Oxygen distribution and vascular injury in the mouse eye measured by phosphorescence-lifetime imaging. Appl Opt (2005) 1.13
Increased expression of ceruloplasmin in the retina following photic injury. Mol Vis (2003) 1.13
Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol Ther (2002) 1.07
Long-term inducible gene expression in the eye via adeno-associated virus gene transfer in nonhuman primates. Hum Gene Ther (2005) 1.07
Accelerated mortality from hydrocephalus and pneumonia in mice with a combined deficiency of SPAG6 and SPAG16L reveals a functional interrelationship between the two central apparatus proteins. Cell Motil Cytoskeleton (2007) 1.07
Disease expression in Usher syndrome caused by VLGR1 gene mutation (USH2C) and comparison with USH2A phenotype. Invest Ophthalmol Vis Sci (2005) 1.06
SCORE Study report #11: incidences of neovascular events in eyes with retinal vein occlusion. Ophthalmology (2011) 1.06
Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis Caused by a Frequent Mutation in CEP290. Mol Ther Nucleic Acids (2012) 1.05
Persistent fetal ocular vasculature in mice deficient in bax and bak. Arch Ophthalmol (2005) 1.04
Nonhuman primate models for diabetic ocular neovascularization using AAV2-mediated overexpression of vascular endothelial growth factor. Diabetes (2005) 1.04
A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated virus. Mol Ther (2002) 1.04
Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. Mol Cell Biol (2010) 1.03
Delivery of adeno-associated virus vectors to the fetal retina: impact of viral capsid proteins on retinal neuronal progenitor transduction. J Virol (2003) 1.02
Gene transfer to ocular stem cells by early gestational intraamniotic injection of lentiviral vector. Mol Ther (2007) 1.02
Plastic surgery residency websites: a critical analysis of accessibility and content. Ann Plast Surg (2014) 1.01
Disruption of CEP290 microtubule/membrane-binding domains causes retinal degeneration. J Clin Invest (2013) 1.01